Dipeptidyl peptidase IV and its inhibitors: Therapeutics for type 2 diabetes and what else?

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2197-2212

  Juillerat Jeanneret, Lucienne ^a  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALOGLIPTIN; ANAGLIPTIN; CARMEGLIPTIN; DA 1229; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; DIPROTIN B; DUTOGLIPTIN; E 3024; GEMIGLIPTIN; GOSOGLIPTIN; INCRETIN; LC 15 0444; LINAGLIPTIN; MELOGLIPTIN; NEW DRUG; OGLYZA; OMARIGLIPTIN; PROLINE; RO 0730699; SAXAGLIPTIN; SITAGLIPTIN; TAK 100; TENEGLIPTIN; TENELIGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; ZEMIGLO; ZOMELIS;

BIOLOGICAL ACTIVITY; CANCER RISK; CARDIOVASCULAR DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME CONFORMATION; ENZYME SUBSTRATE; GLYCEMIC CONTROL; HUMAN; IMMUNOPATHOLOGY; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; TREATMENT INDICATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84897390441     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400658e     Document Type: Review

References (130)

1. Yaron, A.; Naider, F. Proline-dependent structural and biological properties of peptides and proteins Crit. Rev. Biochem. Mol. Biol. 1993, 28, 31-81
2. Busek, P.; Malik, R.; Sedo, A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer Int. J. Biochem. Cell Biol. 2004, 36, 408-421
3. Chen, W. T.; Kelly, T.; Ghersi, G. DPPIV, seprase and related serine peptidases in multiple cellular functions Curr. Top. Dev. Biol. 2003, 54, 207-232
4. Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul. Pept. 1999, 85, 9-24
5. Polgar, L. The prolyl oligopeptidase family Cell. Mol. Life Sci. 2002, 59, 349-362
6. Rosenblum, J. S.; Kosarich, J. W. Prolyl peptidases: a serine protease subfamily with high potential in drug discovery Curr. Opin. Chem. Biol. 2003, 7, 496-504
7. Cunningham, D. F.; O'Connor, B. Proline specific peptidases Biochim. Biophys. Acta 1997, 1343, 160-186
8. Sedo, A.; Malik, R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities Biochem. Biophys. Acta 2001, 1550, 107-116
9. Fleischer, B. CD26: a surface protease involved in T-cell activation Immunol. Today 1994, 15, 180-184
10. Gorrell, M. D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders Clin. Sci. 2005, 108, 277-292
11. Holst, J. J.; Deacon, C. F. Glucagon-like peptides 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus Curr. in. Pharmacol. 2004, 4, 589-596
12. Berger, Y.; Chapuis Bernasconi, C.; Neier, R.; Juillerat-Jeanneret, L. Determination of intracellular prolyl/glycyl-specific proteases in intact living human cells using protoporphyrin IX production as a reporter system Chem. Biol. 2005, 12, 867-872
13. Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H. U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanisms Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5063-5068
14. Hiramatsu, H.; Yamamoto, A.; Kyono, K.; Higashiyama, Y.; Fukushima, C.; Shima, H.; Sugiyama, S.; Inaka, K.; Shimizu, R. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A J. Biol. Chem. 2004, 385, 561-564
15. Rasmussen, H. B.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog Nat. Struct. Biol. 2003, 10, 19-25
16. Oefner, C.; D'Arcy, A.; Mac Sweeney, A.; Pierau, S.; Gardiner, R.; Dale, G. E. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[({2-[85-iodopyridin-2-yl)aminoethyl}amino)acetyl]-2-cyano- (S)-pyrrolodine Acta Crystallogr. 2003, D59, 1206-1212
17. Thoma, R.; Löffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Henning, M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase IV Structure 2003, 11, 947-959
18. Fülöp, V.; Böcskei, Z.; Polgar, L. Prolyl oligopeptidase: an unusual β-propeller domain regulates proteolysis Cell 1998, 94, 161-170
19. Edmondson, S. D.; Mastracchio, A.; Beconi, M.; Colwell, L. F.; Habulihaz, B.; He, H.; Kumar, S.; Leiting, B.; Lyons, K. A.; Mao, A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Zhu, L.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R. Potent and selective proline derived dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 5151-5155
20. Xu, J.; Ok, H. O.; Gonzalez, E. J.; Colwell, L. F.; Habulihaz, B.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E.; Parmee, E. R. Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 4759-4762
21. Xu, J.; Wei, L.; Mathvink, R.; He, J.; Park, Y. J.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A.E. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 2533-2536
22. Xu, J.; Wei, L.; Mathvink, R.; Edmonson, S. D.; Eiermann, G. J.; He, H.; Leone, J. F.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. Discovery of potent,selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 5373-5377
23. Zhao, K.; Lim, D. S.; Funaki, T.; Welch, J. T. Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)- cyclopentanecarbonitrile, a fluoroolefin containing peptido-mimetic Bioorg. Med. Chem. 2003, 11, 207-215
24. Zhao, G.; Taunk, P. C.; Magnin, D. R.; Simpkins, L. M.; Robl, J. A.; Wang, A.; Robertson, J. G.; Marcinkeviciene, J.; Sitkof, D. F.; Parker, R. A.; Kirby, M. S.; Hamann, L. G. Diprolyl nitriles as potent dipeptidylpeptidase IV inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 3992-3995
25. Mentlein, R. Therapeutic assessement of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs Expert Opin. Invest. Drugs 2005, 14, 57-64
26. Leiting, B.; Pryor, K. A.; Wu, J. K.; Marsilio, F.; Patel, R. A.; Craik, C. S.; Ellman, J. A.; Cummings, R. T.; Thornberry, N. A. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII Biochem. J. 2003, 371, 525-532
27. Evans, D. M. Dipeptidyl peptidase IV inhibitors IDrugs 2002, 5, 577-585
28. Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes J. Med. Chem. 2004, 47, 4135-4141
29. Deacon, C. F. MK-431 Merck Curr. Opin. Invest. Drugs 2005, 6, 419-426
30. Holst, J. J.; Deacon, C. F. Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes Diabetes 1998, 47, 1663-1670
31. Juillerat-Jeanneret, L. Prolyl-specific peptidases and their inhibitors in biological processes Curr. Chem. Biol. 1998, 2, 97-109
32. Juillerat-Jeanneret, L.; Gerber-Lemaire, S. The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders Mini-Rev. Med. Chem. 2009, 9, 215-226
33. Plamboeck, A.; Holst, J. J.; Carr, R. D.; Deacon, C. F. Neutral endopeptodase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaestised pig Diabetologia 2005, 48, 1882-1890
34. Ahn, J. H.; Shin, M. S.; Jun, M. A.; Jung, S. H.; Kang, S. K.; Kim, K. R.; Rhee, S. D.; Kang, N. S.; Kim, S. Y.; Sohn, S. K.; Kim, S. G.; Jin, M. S.; Lee, J. O.; Cheon, H. G.; Kim, S. S. Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2622-2628
35. Ahn, J. H.; Park, W. S.; Jun, M. A.; Shin, M. S.; Kang, S. K.; Kim, K. Y.; Rhee, S. D.; Bae, M. A.; Kim, K. R.; Kim, S. G.; Kim, S. Y.; Sohn, S. K.; Kang, N. S.; Lee, J. O.; Lee, D. H.; Cheon, H. G.; Kim, S. S. Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. Lett. 2009, 18, 6525-6529
36. Kuhn, B.; Hennig, M.; Mattei, P. Molecular recognition of ligands in dipeptidyl peptidase IV Curr. Top. Med. Chem. 2007, 7, 609-619
37. Thornberry, N. A.; Weber, A. E. Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type-2 diabetes Curr. Top. Med. Chem. 2007, 7, 557-568
38. White, J. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use Clin. Diabetes 2008, 26, 53-57
39. Feng, J.; Zhang, Z.; Wallace, M.; Stafford, J.; Kaldor, S.; Kassel, D.; Navre, M.; Shi, L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med. Chem. 2007, 50, 2297-2300
40. Belyae, A.; Zhang, X.; Augustyns, K.; Lambeir, A. M.; De Meester, I.; Vedemikova, I.; Scharpe, S.; Haemers, A. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors J. Med. Chem. 1999, 42, 1041-1052
41. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Dunning, B. E.; Mangold, B. L.; Mone, M. D.; Russel, M.E.; Weldon, S. C.; Hughes, T. E. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino] acetyl-2-(S)- pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 2002, 45, 2362-2365
42. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. N. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-3[(3-Hydroxy-1-adamantyl)amino] acetyl-2-cyano-(S)-pyrrolidine, a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 2003, 46, 2774-2789
43. Ferraris, D.; Ko, Y. S.; Calvin, D.; Chiou, T.; Lautar, S.; Thomas, B.; Wozniak, K.; Rojas, C.; Kalish, V.; Belyakoy, S. Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 5579-5583
44. Magnin, D. R.; Robl, J. A.; Sulsky, R. B.; Augeri, D. J.; Huang, Y.; Simpkins, L. M.; Tanks, P. C.; Betebenner, D. A.; Robertson, J. G.; Abboa-Offei, B. E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D. F.; Malley, M. F.; Gougoutas, J. Z.; Khanna, A.; Huang, Q.; Han, S. P.; Parker, R. A.; Hamann, L. G. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5- methanoprolinenitrile- based inhibitors J. Med. Chem. 2004, 47, 2587-2598
45. Peters, J. U.; Weber, S.; Kritter, S.; Weiss, P.; Wallier, A.; Boehringer, M.; Hennig, M.; Kuhn, B.; Loeffler, B. M. Aminomethylpyrimidines as novel DPP-IV inhibitors: a 105-fold activity increase by optimization of aromatic substituents Bioorg. Med. Chem. Lett. 2004, 14, 1491-1493
46. Sakashita, H.; Kitajima, H.; Nakamura, M.; Akahoshi, F.; Hayashi, Y. 1-((S)-γ-Substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 2441-2445
47. Sakashita, H.; Akahoshi, F.; Kitajima, H.; Tsutsumiuchi, R.; Hayashi, Y. [(S)-γ-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors Bioorg. Med. Chem. 2006, 14, 3662-3671
48. Sakashita, H.; Akahoshi, F.; Yoshida, T.; Kitajima, H.; Hayashi, Y.; Ishii, S.; Takashina, Y.; Tsutsumiuchi, R.; Ono, S. Lead optimization of [(S)-γ-(arylamino)prolyl]thiazolidine focused on γ-substituent: indoline compounds as potent DPP-IV inhibitors Bioorg. Med. Chem. 2007, 15, 641-655
49. Haffner, C. D.; McDougald, D. L.; Reister, S. M.; Thompson, B. D.; Conlee, C.; Fang, J.; Bass, J.; Lenhard, J. M.; Croom, D.; Secosky-Chang, M. B.; Tomaszek, T.; McConn, D.; Wells-Knecht, K.; Johnson, P. R. 2-Cyano-4-fluoro-1- thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV Bioorg. Med. Chem. Lett. 2005, 15, 5257-5261
50. Fukushima, H.; Hiratate, A.; Takahashi, M.; Satio, M.; Munetomo, E.; Kitano, K.; Saito, H.; Takaoka, Y.; Yamamoto, K. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2- cyanopyrrolidine dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. 2005, 12, 6053-6061
51. Abe, M.; Akiyama, T.; Umezawa, Y.; Yamamoto, K.; Nagai, M.; Yamazaki, H.; Ichikawa, Y. I.; Muraoka, Y. Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors Bioorg. Med. Chem. 2005, 13, 785-797
52. Gilmore, B. F.; Carson, L.; McShane, L. L.; Quinn, D.; Coulter, W. A.; Walker, B. Synthesis, kinetic evaluation, and utilization of a biotinylated dipeptide proline diphenyl phosphonate for the disclosure of dipeptidyl peptidase IV-like serine proteases Bioorg. Med. Chem. 2006, 347, 373-379
53. Yoshida, T.; Sakashita, H.; Akahoshi, F.; Hayashi, Y. [(S)-γ-(4-Aryl-1-piperazinyl)-l-prolyl] thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2618-2621
54. Kowalchick, J. E.; Leiting, B.; Pryor, K. D.; Marsilio, F.; Wu, J. K.; He, H.; Lyons, K. A.; Eiermann, G. J.; Petrov, A.; Scapin, G.; Patel, R. A.; Thornberry, N. A.; Weber, A. E.; Kim, D. Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-IV) inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5934-5939
55. Corbett, J. W.; Dirico, K.; Song, W.; Boscoe, B. P.; Doran, S. D.; Boyer, D.; Qiu, X.; Ammirati, M.; VanVolkenburg, M. A.; McPherson, R.K.; Parker, J. C.; Cox, E. D. Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide) pyrrolidinyl DPP-IV inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 6707-6713
56. Coumar, M. S.; Chang, C. N.; Chen, C. T.; Chen, X.; Chien, C. H.; Tsai, T. Y.; Cheng, J. H.; Wu, H. Y.; Han, C. H.; Wu, S. H.; Huang, Y. W.; Hsu, T.; Hsu, L. J.; Chao, Y. S.; Hsieh, H. P.; Jiaang, W. T. 3-[2-((2 S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methylbutyramide analogues as selective DPP-IV inhibitors for the treatement of type-II diabetes Bioorg. Med. Chem. Lett. 2077, 17, 1274-1279
57. Biftu, T.; Scapin, G.; Singh, S.; Feng, D.; Becker, J. W.; Eiermann, G.; He, H.; Lyons, K.; Patel, S.; Petrov, A.; Roy, R. S.; Zhang, B.; Wu, J.; Zhang, X.; Doss, G. A.; Thornberry, N. A.; Weber, A. E. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-IV inhibitors by application of molecular modeling and X-ray crystallography of sitaliptin Bioorg. Med. Chem. Lett. 2007, 17, 3384-3387
58. Gao, Y. D.; Feng, D.; Sheridan, R. P.; Scapin, G.; Patel, S. B.; Wu, J. K.; Zhang, X.; Roy, R. S.; Thornberry, N. A.; Weber, A. E.; Biftu, T. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-IV inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3877-3879
59. Kondo, T.; Nekado, T.; Sugimoto, I.; Ochi, K.; Takai, S.; Kinoshita, A.; Hatayama, A.; Yamamoto, S.; Kishikawa, K.; Nakai, H.; Toda, M. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group Bioorg. Med. Chem. Lett. 2008, 16, 1613-1631
60. Peters, J. U. 11 years of cyanopyrrolidines as DPP-IV inhibitors Curr. Top. Med. Chem. 2007, 7, 579-595
61. Liu, Y.; Hu, Y.; Liu, T. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects Curr. Med. Chem. 2012, 19, 3982-3999
62. Miyamoto, Y.; Banno, Y.; Yamashita, T.; Fujimoto, T.; Oi, S.; Moritoh, Y.; Asakawa, T.; Kataoka, O.; Takeuchi, K.; Suzuki, N.; Ikedo, K.; Kosaka, T.; Tsubotani, S.; Tani, A.; Sasaki, M.; Funami, M.; Amano, M.; Yamamoto, Y.; Aertgeerts, K.; Yano, J.; Maezaki, H. Discovery of a 3-pyridylacetamide derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor J. Med. Chem. 2011, 54, 831-850
63. van der Veken, P.; Haemers, A.; Augustyns, K. Prolyl peptidase related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery Curr. Top. Med. Chem. 2007, 7, 621-635
64. Ristic, S.; Byiers, S.; Foley, J.; Holmes, D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response Diabetes, Obes. Metab. 2005, 7, 692-698
65. Russell-Jones, D.; Gough, S. Recent advances in incretin-based therapy Clin. Endocrinol. 2012, 77, 489-499
66. Cox, M. E.; Rowell, J.; Corsino, L.; Green, J. B. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy Drug Healthcare Patient Saf. 2010, 2, 7-19
67. Keeks, E. D. Linagliptin: a review of its use in the management of type 2 diabetes mellitus Drugs 2012, 72, 1793-1824
68. Bohanson, N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice Postgrad. Med. 2009, 121
69. Karagiannis, T.; Paschos, P.; Paletas, K.; Matthews, D. R.; Tsapas, A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 2012, 344, e1369
70. Derosa, G.; Maffioli, P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience Diabetes Technol. Ther. 2012, 14, 350-364
71. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Sinha, R.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2 R)-4-Oxo-4-[3-(trifuloromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a ]pyrazin-7(8 H)-yl]-1-(2,4,5-trifluoro-phenyl)butan-2-amine: a potent orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2005, 48, 141-151
72. Augeri, D. J.; Robl, J. A.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S. P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L G. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2005, 48, 5025-5037
73. Eckhardt, M.; Langkop, E.; Mark, M.; Tadayyon, M.; Thomas, L.; Nar, H.; Pfengle, W.; Guth, B.; Lotz, R.; Siegel, P.; Fuchs, H.; Himmelsbach, E. 8-[(3 R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2- yl)methyl]-3,7-dihydro-1 H -purine-2,6-dione (BI-1356) a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type-2 diabetes J. Med. Chem. 2007, 50, 6450-6453
74. Lim, K. S.; Cho, J. Y.; Kim, B. H.; Kim, J. R.; Kim, H. S.; Kim, D. K.; Kim, S. H.; Yim, H. J.; Lee, S. H.; Shin, S. G.; Jang, I. J.; Yu, K. S. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitors, after multiple dosing in healthy volunteers Br. J. Clin. Pharmacol. 2009, 68, 883-890
75. Yang, S. J.; Min, K. W.; Gupta, S. K.; Park, J. Y.; Shivane, V. K.; Pitale, S. U.; Agarwal, P. K.; Sosale, A.; Gandhi, P.; Dharmalingam, M.; Mohan, V.; Makesh, U.; Kim, D. M.; Kim, J. A.; Kim, P. K.; Baik, S. H. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes Diabetes, Obes. Metab. 2013, 15, 410-416
76. Agrawal, R.; Pratima, J.; Dikshit, S. N. Linagliptin, a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor Curr. Drug Targets 2012, 13, 970-983
77. Scheen, A. J. A review of gliptins in 2011 Expert Opin. Pharmacother. 2012, 13, 81-99
78. Gueler, I.; Mueller, S.; Helmschrott, M.; Oeing, C. U.; Erbel, C.; Frankenstein, L.; Gleissner, C.; Ruhpaewar, A.; Ehlerman, P.; Dengler, T. J.; Katus, H. A.; Doesch, A. O. Effects of vildagliptin (galvus) therapy in patients with type 2 diabetes Drug Des. Dev. Ther. 2013, 7, 297-303
79. Matteuchi, E.; Gianpietro, O. Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety Curr. Med. Chem. 2011, 18, 4753-4760
80. Gupta, V.; Kaltra, S. Choosing a gliptin Int. J. Endocrinol. Metab. 2011, 15, 298-308
81. Aleskow Stein, S.; Lamos, E. M.; Davis, S. N. A review of the efficacy and safety of oral antidiabetic drugs Expert Opin. Drug Saf. 2013, 12, 153-175
82. Landesdorfer, C. B.; He, Y. L.; Jusko, W. J. Mechanism-based population pharmacokinetic modeling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV Br. J. Clin. Pharmacol. 2011, 73, 391-401
83. Gross, J. L.; Rogers, J.; Polhamus, D.; Gillespie, W.; Friedrich, C.; Gong, Y.; Monz, B. U.; Patel, S.; Staabm, A.; Retlich, S. A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, intreatment of type 2 diabetes mellitus BMJ Open 2013, 3, e001844
84. Ervinna, N.; Mita, T.; Yasunari, E.; Azuma, K.; Tanaka, R.; Fujimura, S.; Sukmawati, D.; Nomiyama, T.; Kanazawa, A.; Kawamori, R.; Fujitani, Y.; Watada, H. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice Endocrinology 2013, 154, 1260-1270
85. Kato, N.; Oka, M.; Murase, T.; Yoshida, M.; Sakairi, M.; Yakufu, M.; Yamashita, S.; Yasuda, Y.; Yoshikawa, A.; Hayashi, Y.; Shirai, M.; Mizuno, Y.; Takeuchi, M.; Makino, M.; Takeda, M.; Kakigami, T. Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors Org. Med. Chem. Lett. 2011, 1, 7
86. Kim, M. K.; Chae, Y. N.; Kim, H. D.; Yang, E. K.; Cho, E. J.; Choi, S. H.; Cheong, Y. H.; Kim, H. S.; Kim, H. J.; Jo, Y. W.; Son, M. H.; Kim, S. H.; Shin, C. Y. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes Life Sci. 2012, 90, 21-29
87. Yasuda, N.; Nagakura, T.; Inoue, T.; Yamazaki, K.; Katsutani, N.; Takenaka, O.; Clark, R.; Matsuura, F.; Emori, E.; Yoshikawa, S.; Kira, K.; Ikuta, H.; Okada, T.; Saeki, T.; Asano, O.; Tanaka, I. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro- 4H -imidazo[4,5- d ]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase IV inhibitor Eur. J. Pharmacol. 2006, 548, 181-187
88. Biftu, T. MK-3102: A Novel Once-Weekly DPP IV Inhibitor for Type 2 Diabetes. Presented at the Society for Medicines Research Research Symposium, December 5, 2012, London, U.K.
89. Brunavs, M.; Cowley, P.; Ward, S. E.; Weber, P. Recent disclosures of clinical candidates Drugs Future 2013, 38, 127-133
90. Akarte, A. S.; Srinvasan, B. P.; Gandhi, S. A novel long-acting DPP-IV inhibitor PKF-275-055 stimulated cell proliferation resulting in improved glucose homeostasis in diabetics rats Biochem. Pharmacol. 2012, 83, 241-252
91. Sutton, J. M.; Clark, D. E.; Dunsdon, S, J.; Fenton, G.; Fillmore, A.; Harris, N. V.; Higgs, C.; Hurley, C. A.; Krintel, S. L.; MacKenzie, R. E.; Duttaroy, A.; Gangl, E.; Maniara, W.; Sedrani, R.; Namoto, K.; Ostermann, N.; Gerhartz, B.; Sirockin, F.; Trappe, J.; Hassiepen, U.; Baeschlin, D. K. Novel heterocyclic DPP-IV inhibitors for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 2012, 22, 1464-1468
92. Jadav, P.; Bahekar, R.; Shah, S. R.; Patel, D.; Joharapurkar, A.; Kshirsagar, S.; Jain, M.; Shaikh, M.; Sairam, K. V. Long-acting peptidomimetics based DPP-IV inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 3516-3521
93. Kim, H. J.; Kwak, W. Y.; Min, J. P.; Sung, S. Y.; Kim, H. D.; Kim, M. K.; Kim, H. S.; Park, K. J.; Son, M. H.; Kim, S. H.; Lee, B. J. Dipeptidyl peptidase-4 inhibitors with β-amino amide scaffold; synthesis, SAR and biological evaluation Bioorg. Med. Chem. Lett. 2012, 22, 5545-5549
94. Shan, Z.; Peng, M.; Fan, H.; Lu, Q.; Lu, P.; Zhao, C.; Chen, Y. Discovery of potent dipeptidyl peptidase IN inhibitors derived from β-aminoamides bearing substituted [1,2,3]-triazolopiperidines for the treatment of type 2 diabetes Bioorg. Med. Chem. Lett. 2011, 21, 1731-1735
95. Xie, H.; Zeng, L.; Zeng, S.; Lu, X.; Zhang, G.; Zhao, X.; Cheng, N.; Tu, Z.; Li, Z.; Xu, H.; Yang, Y. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization Eur. J. Med. Chem. 2012, 52, 205-212
96. Li, C.; Lu, W.; Lu, C.; Xia, W.; Shen, X.; Huang, J.; Liu, G.; Tang, Y. Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening J. Mol. Model. 2012, 18, 4033-4042
97. Wu, D.; Jin, F.; Lu, W.; Zhu, J.; Li, C.; Wang, W.; Tang, Y.; Jiang, H.; Huang, J.; Liu, G.; Li, J. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors Chem. Biol. Drug Des. 2012, 79, 897-906
98. Zhang, L.; Su, M.; Li, J.; Ji, X.; Wang, J.; Li, Z.; Li, J.; Liu, H. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors Chem. Biol. Drug Des. 2013, 81, 198-207
99. Lin, K.; Cai, Z.; Wang, F.; Zhang, W.; Zhou, W. Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4 Chem. Pharm. Bull. 2013, 61, 477-482
100. Juillerat-Jeanneret, L.; Robert, M. C.; Juillerat, M. A. Peptides from Lactobacillus hydrolysates of bovine milk caseins inhibit prolyl-peptidases of human colon cells J. Agric. Food Chem. 2011, 59, 370-377
101. Li-Chan, E. C. Y.; Huang, S. L.; Jao, C. L.; Ho, K. P.; Hsu, K. C. Peptides derived from atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors J. Agric. Food Chem. 2012, 60, 973-978
102. Huang, S. L.; Jao, C. L.; Ho, K. P.; Hsu, K. C. Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates Peptides 2012, 35, 114-121
103. Hsiung, H. M.; Smiley, D. L.; Zhang, X. Y.; Zhang, L.; Yan, L. Z.; Craft, L.; Heiman, M. L.; Smith, D. P. Potent peptide agonists for human melanocortin 3 and 4 receptors derived from enzymatic cleavage of human β-MSH(5-22) by dipeptidyl peptidase I and dipeptidyl peptidase IV Peptides 2005, 26, 1988-1996
104. Rosmanho-Salgado, J.; Marques, J. P.; Estrada, M.; Santana, M.; Cortez, Y.; Grouzman, E.; Cavadas, C. Dipeptidyl-peptidase IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-expression Peptides 2012, 37, 49-54
105. Jackson, E. K.; Kochanek, S. J.; Gillespie, D. G. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells Hypertension 2012, 60, 757-764
106. Liu, W. J.; Xie, S. H.; Liu, Y. N.; Kim, W.; Jin, H. Y.; Park, S. K.; Shao, Y. M.; Park, T. S. Dipeptidyl peptidase IV inhibitor attenuate kidney injury in streptozotocin-induced diabetic rats J. Pharmacol. Exp. Ther. 2012, 340, 248-255
107. Sangle, G. V.; Läuffer, L. M.; Grieco, A.; Trivedi, S.; Iaboukov, R.; Brubaker, P. L. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue Endocrinology 2012, 153, 564-573
108. Pethiyagoda, C. L.; Welch, D. R.; Fleming, T. P. Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells Clin. Exp. Metastasis 2001, 18, 391-400
109. Wesley, U. V.; Albino, A. P.; Tiwari, S.; Houghton, A. N. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells J. Exp. Med. 1999, 190, 311-322
110. Wesley, U. V.; Tiwari, S.; Houghton, A. N. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells Int. J. Cancer 2004, 109, 855-866
111. Bogenrieder, T.; Finstad, C. L.; Freeman, R. H.; Papandreou, C. N.; Scher, H. I.; Albino, A. P.; Reuter, V. E.; Nanus, D. M. Expression and localization of aminopeptidase A, aminopeptidase N and dipeptidyl peptidase IV in benign and malignant human prostate tissue Prostate 1997, 33, 225-232
112. Asada, Y.; Aratake, Y.; Kotani, T.; Marutsuka, K.; Araki, Y.; Ohtaki, S.; Sumiyoshi, A. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma Histopathology 1993, 23, 265-270
113. Kajiyama, H.; Kikkawa, F.; Ino, K.; Shibata, K.; Mizutani, S. Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade Adv. Exp. Med. Biol. 2003, 524, 245-248
114. Kikkawa, F.; Kajiyama, H.; Shibata, K.; Ino, K.; Nomura, S.; Mitzutani, S. Dipeptidyl peptidase IV in tumor progression Biochim. Biophys. Acta 2005, 1751, 45-51
115. Kajiyama, H.; Kikkawa, F.; Khin, E.; Shibata, K.; Ino, K.; Mizutani, S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells Cancer Res. 2003, 63, 2278-2283
116. Juillerat-Jeanneret, L.; Monnet-Tschudi, F.; Zürich, M. G.; Lohm, S.; Duijvestijn, A. M.; Honegger, P. Regulation of peptidase activity in a three-dimensional aggregate model of brain tumor vasculature Cell Tissue Res. 2003, 311, 53-59
117. Adams, S.; Miller, G. T.; Jesson, M. I.; Watanabe, T.; Jones, B.; Wallner, B. P. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism Cancer Res. 2004, 64, 5471-5480
118. Arwert, E. N.; Mentink, R. A.; Driskell, R. R.; Hoste, E.; Goldie, S. J.; Quist, S.; Watt, F. M. Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumor formation Oncogene 2012, 31, 992-1000
119. Steinbrecher, A.; Reinhold, D.; Quigley, L.; Gado, A.; Tresser, N.; Izikson, L.; Born, I.; Faust, J.; Neubert, K.; Martin, R.; Ansorge, S.; Brocke, S. Dipeptidyl peptidase IV in inflammatory CNS disease Adv. Exp. Biol. Med. 2000, 477, 145-153
120. Wrenger, S.; Faust, J.; Mrestani-Klaus, C.; Fengler, A.; Stockel-Maschek, A.; Lorey, S.; Kahne, T.; Brandt, W.; Neubert, K.; Ansorge, S.; Reinhold, D. Downregulation of T-cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the throboxane A2 receptor J. Biol. Chem. 2000, 275, 22180-22186
121. Hillebrandt, M.; Rose, M.; Rüter, J.; Salama, A.; Mönnikes, H.; Klapp, B. F. Dipeptidylpeptidase IV (DP IV, CD26) in patients with inflammatory bowel disease Scand. J. Gastroenterol. 2001, 10, 1067-1072
122. Sedo, A.; Vlasicova, K.; Bartak, P.; Vespalec, R.; Vicar, J.; Simanek, V.; Ulrichova, J. Quaternary benzo[ c ]phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV Phytother. Res. 2002, 16, 84-87
123. Busso, N.; Wagtmann, N.; Herling, C.; Chobaz-Péclat, V.; Bischof-Delaloye, A.; So, A.; Grouzman, E. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis Am. J. Pathol. 2005, 166, 433-442
124. Reinhold, D.; Hemmer, B.; Gran, B.; Steinbrecher, A.; Brocke, S.; Kahne, T.; Wrenger, S.; Born, I.; Faust, J.; Neubert, K.; Martin, R.; Ansorge, S. Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease Adv. Exp. Med. Biol. 2000, 477, 155-160
125. Matsubara, J.; Sigiyama, S.; Sugamura, K.; Nakamura, T.; Fijiwara, Y.; Akiyama, E.; Kurokawa, H.; Nozaki, T.; Ohba, K.; Konishi, M.; Maeda, H.; Izumiya, Y.; Kaikita, K.; Sumida, H.; Jinnouchi, H.; Matsui, K.; Mitsuyama, S. K.; Takeya, M.; Ogawa, H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice J. Am. Coll. Cardiol. 2012, 59, 265-276
126. Marchetti, C.; Di Carlo, A.; Facchiano, F.; Senatore, C.; De Cristofaro, R.; Luzi, A.; Federici, M.; Romani, M.; Napolitano, M.; Capogrossi, M. C.; Germane, A. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV Diabetologia 2012, 55, 236-244
127. Matheeussen, V.; Jungrathmayr, W.; De Meester, I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury Pharmacol. Ther. 2012, 136, 267-282
128. Jungraithmayr, W.; De Meester, I.; Matheeussen, V.; Baerts, L.; Arni, S.; Weder, W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation Eur. J. Cardio-Thorac. Surg. 2012, 41, 1166-1173
129. Corbett, A.; Pickett, J.; Burns, A.; Corcoran, J.; Dunnett, S. B.; Edison, P.; Hagan, J. J.; Holmes, C.; Jones, E.; Katona, C.; Kearns, I.; Kehoe, P.; Mudher, A.; Passmore, A.; Shepherd, N.; Walsh, F.; Ballard, C. Drug repositioning for Alzheimer's disease Nat. Rev. Drug Discovery 2012, 11, 833-846
130. Kim, D. H.; Huh, J. W.; Jang, M.; Suh, J. H.; Kim, T. W.; Park, J. S.; Yoon, S. Y. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures Neurobiol. Dis. 2012, 46, 52-58